Načítá se...
Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy?
The world is facing a viral pandemic of a new coronavirus called COVID‐19. Pentoxifylline is a methyl‐xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti‐inflammatory agent, also it could have antiviral aff...
Uloženo v:
| Vydáno v: | Dermatol Ther |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7300917/ https://ncbi.nlm.nih.gov/pubmed/32473070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.13733 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|